Biogen Q3 Revenue Rises 11% to $2.8 Billion; Raises EPS Guidance

What happened

Biogen reported third-quarter 2026 revenue of $2.8 billion, up 11% from a year earlier. Non-GAAP diluted EPS was $2.62, while GAAP diluted EPS was a loss of $0.14. It raised the low end of full-year non-GAAP EPS guidance to $12.20.

Confirmed

Global impact / market context

Higher revenue and a raised profit floor suggest Biogen's core business is stabilizing after a weak profit year. But the GAAP loss, driven by deal-related charges, shows that buying new products can lift sales while still weighing on reported earnings.

Analyst inference

Investors compare GAAP and non-GAAP figures closely here: non-GAAP, which excludes certain charges, is down sharply year over year. The raised guidance floor may reassure holders, but the gap between the two measures keeps attention on acquisition costs.

Analyst inference

What to watch

1. Full-year 2026 revenue is expected to rise by a mid-single-digit percentage, and non-GAAP diluted EPS guidance is now $12.20 to $13.00, up from $12.00 to $13.00. Confirmed
2. Phase 3 TOPAZ-1 and TOPAZ-2 readouts are expected, which are late-stage trial results that could support future revenue if successful, though the article does not state a date. Confirmed
3. Watch whether the acquired Apellis products keep adding revenue and whether deal-related charges keep causing GAAP losses, since both affect how investors judge profit quality. Analyst inference

Evidence

• Original source link unavailable